Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2025 (the "Reporting Period").
Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552.HK) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the Department of Health of the Hong Kong Special Administrative Region of China for the treatment of Type 2 diabetes in adults.
Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552.HK) announced that the multiple-ascending dose (MAD) Phase Ib clinical trial of HMS1005 (formerly known as HM-002-1005), a second-generation glucokinase activator (GKA) independently developed by the Company, has successfully completed the first patient dosing in the United States.
ir@huamedicine.com
No.275 Ai Di Sheng Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203
沪公网安备 31011502013809号 Privacy Statement Terms of Use
